Indegene Ltd.
INDGN · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹483.12.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%13.9%
- ✓Low debt (D/E < 0.5)0.05x
- ✓Positive free cash flow
- ✓Revenue growth > 10%33%
- ✕Earnings growing-32%
- ✓Net margin ≥ 10%11.4%
- ✓Current ratio > 1.52.41
- ✓Below our fair value
- ✕Margin of safety ≥ 20%
- ✕Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 6.38
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 6.38.
Weaknesses
- •Price below its 200-day moving average (downtrend).
Opportunities
- •Revenue growing (33% YoY).
- •Trading in our value buy zone versus sector peers.
Threats
- •Earnings contracting year on year.
About Indegene Ltd.
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, and internationally. It operates through three segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation & Others. The company develops biotech and medical device for biopharmaceutical, emerging biotech, and medical device companies
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.